Thank you for your inquiry regarding CMS645v7. Guidance from CMS states that implementers can map from the generic pack RxCUI to the branded SCD RxCUI according to measure intention. From CMS on RxNorm Use in Quality Measures, “While the Blueprint content includes branded TTYs in the guidance, authoring guidance has encouraged measure developers not to include branded term types because changes in branded identifiers for any single general drug (such as a Semantic Clinical Drug [SCD]) occur throughout the year and, even with the inclusion of value set addendum releases, there can be value sets that are out of sync with some implementer system content. Also, it provides for impartiality reducing the perception of branded drug favoritism. Given that RxNorm application content (and all drug information vendor products) can be used to map from the more stable general identifier to a branded identifier, and from other code systems such as National Drug Code (NDC) or proprietary code systems, the branded RxNorm TTYs were often not included under the assumption that if an implementer had a different identifier, the implementer could map to the included SCD RXCUI or generic pack (GPCK) RXCUI or any other TTY and ID according to the intention.” https://mmshub.cms.gov/measure-lifecycle/measure-specification/specify-code/RxNorm

CMS Measure ID CMS645, Titled: Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy is only accepting Active, Medication Orders in the generic form? When I look at the ValueSets for this measures, specifically the Androgen Deprivation therapy for urology Care, the RXNorm codes are all associated with generic forms of the ADT medication. I looked through the measure specifications and I do not find any guidance on why the brand name ADT drugs are not accepted. For example, Eligard, has an RXNorm code that is not accepted according to this valueset